(-)-Cryptopleurine
Based on 1 Customer Validation
(–)-Cryptopleurine is an alkaloid that has been found in Lauraceae and has diverse biological activities. It inhibits the growth of human A375 melanoma, A431 epidermoid carcinoma, A549 lung, MES-SA uterine sarcoma, and MCF-7 breast cancer cells (IC50=3 nM for all).2 (–)-Cryptopleurine inhibits hypoxia-induced gene expression in a hypoxia response element (HRE) reporter assay (IC50=8.7 nM).3 (–)-Cryptopleurine (500 μg/mL) prevents lesion formation in tobacco (N. tabacum) plants infected with tobacco mosaic virus (TMV). It also inhibits protein synthesis by yeast and mammalian ribosomes.
For research use only. We do not sell to patients.
- Purity : 98%
- CAS No.: 482-22-4
- Formula: C24H27NO3
- Molecular Weight:377.48
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
0.003 μM
Compound: (-)-2
|
Cytotoxicity against human melanoma, A375 cells
Cytotoxicity against human melanoma, A375 cells
|
[PMID: 16236503] |
| A-375 | IC50 |
1.2 nM
Compound: (-)-1
|
Antiproliferative activity against human A375 cells after 72 hrs by ATPlite assay
Antiproliferative activity against human A375 cells after 72 hrs by ATPlite assay
|
[PMID: 25499434] |
| A-431 | IC50 |
0.003 μM
Compound: (-)-2
|
Cytotoxicity against human epidermoid carcinoma, A431 cells
Cytotoxicity against human epidermoid carcinoma, A431 cells
|
[PMID: 16236503] |
| A549 | GI50 |
<0.001 μM
Compound: 36
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 22417638] |
| A549 | GI50 |
1.38 nM
Compound: R-cryptopleurine
|
Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay
Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21668000] |
| A549 | IC50 |
0.003 μM
Compound: (-)-2
|
Cytotoxicity against human lung carcinoma, A549 cells
Cytotoxicity against human lung carcinoma, A549 cells
|
[PMID: 16236503] |
| A549 | IC50 |
0.94 nM
Compound: 2
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 26393416] |
| A549 | IC50 |
1.38 nM
Compound: cryptopleurine
|
Cytotoxicity against human A549 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis
Cytotoxicity against human A549 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis
|
[PMID: 22823514] |
| A549 | IC50 |
1.9 nM
Compound: (-)-1
|
Antiproliferative activity against human A549 cells after 72 hrs by ATPlite assay
Antiproliferative activity against human A549 cells after 72 hrs by ATPlite assay
|
[PMID: 25499434] |
| A549 | IC50 |
1.9 nM
Compound: cryptopleurine
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 22823514] |
| AGS | IC50 |
8.7 nM
Compound: 1
|
Inhibition of hypoxia-induced HIF1 activation in human AGS cells after 16 hrs by pGL3-HRE-luciferase reporter gene assay
Inhibition of hypoxia-induced HIF1 activation in human AGS cells after 16 hrs by pGL3-HRE-luciferase reporter gene assay
|
[PMID: 16872154] |
| BT-20 | IC50 |
0.003 μM
Compound: (-)-2
|
Cytotoxicity against human breast carcinoma, BT20 cells
Cytotoxicity against human breast carcinoma, BT20 cells
|
[PMID: 16236503] |
| BUD-8 | IC50 |
0.006 μM
Compound: (-)-2
|
Cytotoxicity against human fibroblast, BUD8 cells
Cytotoxicity against human fibroblast, BUD8 cells
|
[PMID: 16236503] |
| CAKI-1 | IC50 |
0.86 nM
Compound: 2
|
Cytotoxicity against human Caki1 cells assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against human Caki1 cells assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 26393416] |
| CL1-0 | IC50 |
5 nM
Compound: cryptopleurine
|
Cytotoxicity against human CL1-0 cells assessed as cell viability after 48 hrs by SRB assay
Cytotoxicity against human CL1-0 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 22823514] |
| Daudi | IC50 |
0.002 μM
Compound: (-)-2
|
Cytotoxicity against human Burkitt lymphoma, DAUDI cells
Cytotoxicity against human Burkitt lymphoma, DAUDI cells
|
[PMID: 16236503] |
| DU-145 | GI50 |
1.59 nM
Compound: R-cryptopleurine
|
Anticancer activity against human DU145 cells after 72 hrs by sulforhodamine B assay
Anticancer activity against human DU145 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21668000] |
| DU-145 | IC50 |
1.59 nM
Compound: cryptopleurine
|
Cytotoxicity against human DU145 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis
Cytotoxicity against human DU145 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis
|
[PMID: 22823514] |
| HCT-116 | IC50 |
0.7 nM
Compound: (-)-1
|
Antiproliferative activity against human HCT116 cells after 72 hrs by ATPlite assay
Antiproliferative activity against human HCT116 cells after 72 hrs by ATPlite assay
|
[PMID: 25499434] |
| HCT-116 | IC50 |
1.04 nM
Compound: 2
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 26393416] |
| HCT-15 | IC50 |
0.003 μM
Compound: (-)-2
|
Cytotoxicity against human colon carcinoma, HCT15 cells
Cytotoxicity against human colon carcinoma, HCT15 cells
|
[PMID: 16236503] |
| HCT-8 | GI50 |
1.09 nM
Compound: R-cryptopleurine
|
Anticancer activity against human HCT8 cells after 72 hrs by sulforhodamine B assay
Anticancer activity against human HCT8 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21668000] |
| HCT-8 | IC50 |
1.91 nM
Compound: cryptopleurine
|
Cytotoxicity against human HCT8 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis
Cytotoxicity against human HCT8 cells after 2 hrs by methylene blue staining-based spectrophotometric analysis
|
[PMID: 22823514] |
| HepG2 2.2.15 | IC50 |
6.3 nM
Compound: Cryptopleurine
|
Cytotoxicity against human HepG2(2.2.15) cells assessed as cell growth inhibition
Cytotoxicity against human HepG2(2.2.15) cells assessed as cell growth inhibition
|
[PMID: 29317151] |
| HL-60 | GI50 |
<0.001 μM
Compound: 36
|
Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay
Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay
|
[PMID: 22417638] |
| HT-1376 | IC50 |
0.004 μM
Compound: (-)-2
|
Cytotoxicity against human bladder carcinoma, HT1376 cells
Cytotoxicity against human bladder carcinoma, HT1376 cells
|
[PMID: 16236503] |
| HUVEC | GI50 |
11 nM
Compound: R-cryptopleurine
|
Toxicity against HUVEC
Toxicity against HUVEC
|
[PMID: 21668000] |
| KB | GI50 |
1.51 nM
Compound: R-cryptopleurine
|
Anticancer activity against human KB cells after 72 hrs by sulforhodamine B assay
Anticancer activity against human KB cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21668000] |
| KB | IC50 |
1.51 nM
Compound: cryptopleurine
|
Cytotoxicity against human KB cells after 2 hrs by methylene blue staining-based spectrophotometric analysis
Cytotoxicity against human KB cells after 2 hrs by methylene blue staining-based spectrophotometric analysis
|
[PMID: 22823514] |
| KHOS/NP | IC50 |
0.01 μM
Compound: (-)-2
|
Cytotoxicity against human osteosarcoma, KHOS-NP cells
Cytotoxicity against human osteosarcoma, KHOS-NP cells
|
[PMID: 16236503] |
| MAT-Ly-Lu | IC50 |
0.003 μM
Compound: (-)-2
|
Cytotoxicity against rat prostate carcinoma, MatLyLu cells
Cytotoxicity against rat prostate carcinoma, MatLyLu cells
|
[PMID: 16236503] |
| MCF7 | IC50 |
0.003 μM
Compound: (-)-2
|
Cytotoxicity against human breast carcinoma, MCF7 cells
Cytotoxicity against human breast carcinoma, MCF7 cells
|
[PMID: 16236503] |
| MDA-MB-231 | IC50 |
0.89 nM
Compound: 2
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 26393416] |
| MES-SA | IC50 |
0.003 μM
Compound: (-)-2
|
Cytotoxicity against human uterine sarcoma, MES-SA cells
Cytotoxicity against human uterine sarcoma, MES-SA cells
|
[PMID: 16236503] |
| MES-SA/Dx5 | IC50 |
0.003 μM
Compound: (-)-2
|
Cytotoxicity against human uterine sarcoma, MES-SA-Dx5 cells derived from MES-SA
Cytotoxicity against human uterine sarcoma, MES-SA-Dx5 cells derived from MES-SA
|
[PMID: 16236503] |
| MRC5 | IC50 |
14 nM
Compound: cryptopleurine
|
Cytotoxicity against human MRC5 cells assessed as cell viability after 48 hrs by SRB assay
Cytotoxicity against human MRC5 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 22823514] |
| NAMALVA | IC50 |
2.6 nM
Compound: (-)-1
|
Antiproliferative activity against human NAMALWA cells after 72 hrs by ATPlite assay
Antiproliferative activity against human NAMALWA cells after 72 hrs by ATPlite assay
|
[PMID: 25499434] |
| PA-1 | IC50 |
0.002 μM
Compound: (-)-2
|
Cytotoxicity against human ovarian teratocarcinoma, PA1 cells
Cytotoxicity against human ovarian teratocarcinoma, PA1 cells
|
[PMID: 16236503] |
| PC-3 | IC50 |
2.55 nM
Compound: 2
|
Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 26393416] |
| PC-9 | IC50 |
5.5 nM
Compound: cryptopleurine
|
Cytotoxicity against human PC9 cells assessed as cell viability after 48 hrs by SRB assay
Cytotoxicity against human PC9 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 22823514] |
| Ramos | IC50 |
0.003 μM
Compound: (-)-2
|
Cytotoxicity against human Burkitt lymphoma, RAMOS cells
Cytotoxicity against human Burkitt lymphoma, RAMOS cells
|
[PMID: 16236503] |
| SK-HEP1 | IC50 |
0.83 nM
Compound: 2
|
Cytotoxicity against human SKHEP1 cells assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against human SKHEP1 cells assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 26393416] |
| SNU-638 | IC50 |
1.26 nM
Compound: 2
|
Cytotoxicity against human SNU638 cells assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against human SNU638 cells assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 26393416] |
Chemical Information
-
CAS No. 482-22-4
-
Appearance Solid
-
Molecular Weight 377.48
-
Formula C24H27NO3
-
Color White to off-white
-
SMILES
COC1=CC2=C3C=C(C(OC)=CC3=C4C[C@]5(CCCCN5CC4=C2C=C1)[H])OC
-
Synonyms
(R)-Cryptopleurine; NSC 19912
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Dual Luciferin reporter gene assay
Luciferin reporter gene assay is a reporting system to detect the activity of Firefly Luciferase using luciferin as a substrate, which is often used in the research of miRNA target gene verification and promoter transcriptive activity regulation. Dual luciferase usually refers to Firefly luciferase and Renilla luciferase.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)